Document Detail

New approaches for identifying antiarrhythmic drug targets.
MedLine Citation:
PMID:  14996613     Owner:  NLM     Status:  MEDLINE    
Sudden cardiac death, secondary to ventricular fibrillation (VF), remains the leading cause of death in many developed countries. Substantial experimental and theoretical support exists for the idea that VF is caused by spiral wave re-entry. The initiation and subsequent break-up of spiral waves have been linked to electrical alternans, a phenomenon typically associated with a steeply sloped restitution relationship. Interventions that reduce the slope of the restitution relationship have been shown to prevent the induction of VF and to terminate existing VF in experimental models. These results suggest that electrical restitution may be a promising new target for antiarrhythmic therapies.
Robert F Gilmour
Related Documents :
2481283 - Sequential pulse countershock between two transvenous catheters: feasibility, safety, a...
19939743 - Incidence and predictors of mortality following ablation of ventricular tachycardia in ...
20467933 - Isolated dextrocardia with situs solitus (dextroversion).
Publication Detail:
Type:  Editorial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Expert opinion on therapeutic targets     Volume:  8     ISSN:  1744-7631     ISO Abbreviation:  Expert Opin. Ther. Targets     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-03-03     Completed Date:  2005-12-06     Revised Date:  2008-10-28    
Medline Journal Info:
Nlm Unique ID:  101127833     Medline TA:  Expert Opin Ther Targets     Country:  England    
Other Details:
Languages:  eng     Pagination:  1-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Action Potentials / drug effects
Adrenergic beta-Antagonists / therapeutic use
Anti-Arrhythmia Agents / pharmacology*,  therapeutic use
Calcium / metabolism
Calcium Channel Blockers / therapeutic use
Calcium Channels / drug effects,  physiology
Clinical Trials as Topic
Death, Sudden, Cardiac / prevention & control*
Drug Design*
Drug Evaluation, Preclinical
Electrocardiography / drug effects
Ether-A-Go-Go Potassium Channels / genetics,  physiology
Genetic Vectors / genetics,  therapeutic use
Heart Conduction System / drug effects*
Ion Channel Gating / drug effects*
Models, Cardiovascular
Phosphorylation / drug effects
Potassium / metabolism
Potassium Channels / drug effects,  physiology
Protein Processing, Post-Translational / drug effects
Transduction, Genetic
Ventricular Fibrillation / drug therapy*,  physiopathology
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Anti-Arrhythmia Agents; 0/Calcium Channel Blockers; 0/Calcium Channels; 0/ERG1 potassium channel; 0/Ether-A-Go-Go Potassium Channels; 0/Potassium Channels; 7440-09-7/Potassium; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers.
Next Document:  Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression.